Navigation Links
Ibuprofen associated with slower lung function decline in children with cystic fibrosis
Date:11/30/2007

Treatment with ibuprofen is associated with a significantly slower rate of decline in lung function in children and adolescents with cystic fibrosis, according to a new study.

Researchers found that patients with cystic fibrosis (CF) who took high doses of ibuprofen had a 29 percent reduction in loss of lung function compared to those who did not use the anti-inflammatory drug twice daily over a period of two to seven years.

It is fairly evident that the lung damage that occurs in cystic fibrosis is due to inflammation, and that this lung damage is what shortens the lives of these patients, said lead researcher Michael W. Konstan, M.D., Director of the Cystic Fibrosis Center at Rainbow Babies and Children's Hospital, and a professor of pediatrics at Case Western Reserve University School of Medicine in Cleveland. Since ibuprofen is an anti-inflammatory drug, we presume that it works by decreasing inflammation in the lung, thereby slowing damage.

The study, which concluded that the benefits of ibuprofen therapy outweigh the small risk of gastrointestinal bleeding, appears in the first issue for December 2007 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Cystic fibrosis is a genetic disorder that causes mucus to be thick and sticky. The mucus clogs the lungs, which causes breathing problems and makes it easy for bacteria to grow. The persistence of bacterial infections leads to chronic inflammation, causing lung damage, which eventually proves fatal.

Dr. Konstan led a clinical trial 12 years ago that found ibuprofen reduced the loss of lung function in CF patients, but questions have remained about the safety of regular high-dose ibuprofen use, which in some cases can lead to gastrointestinal bleeding. This study showed that gastrointestinal bleeding was rare, with an annual incidence of 0.37 percent in those taking ibuprofen, compared with 0.14 percent in those not taking the drug.

There is still some concern about the safety of ibuprofen, Dr. Konstan noted. Although we found only a small increase in gastrointestinal bleeding due to ibuprofen, we continue to search for even safer approaches to anti-inflammatory treatment for CF. In the meantime, we think that CF patients, especially children and adolescents with early lung disease, should be treated with ibuprofen.

While the earlier trial was conducted under tightly controlled conditions to ensure that patients strictly adhered to their medication regimens, the new study looked at real-world use of ibuprofen. In a clinical trial, things are done very carefully, and we dont know if the findings hold true in clinical practice, explained Dr. Konstan. The new studywhich used data from 1996 to 2002 on patients from ages 6 to 17 who were part of the Cystic Fibrosis Foundation Patient Registryconfirms that ibuprofen therapy works in the real world.

The new study included data on 1,365 patients who took ibuprofen and 8,960 who did not, who were of similar age and disease severity. Each dose of ibuprofen ranged from 20 to 30 milligrams per kilogram of the patients weight. Some patients took up to 1,600 milligrams of ibuprofen per dose. (Generally, over-the-counter preparations of ibuprofen advise a maximum daily dose of 1,200 mg for adults and children over the age of 12.)

While the research does not address whether CF patients who take ibuprofen live longer, Dr. Konstan said it is likely the case. The lung function of these patients declines over time, and rate of decline is associated with survival, he said. Although we dont have evidence to prove it, we would like to think that this slowing of lung function decline due to ibuprofen therapy translates into increased years of survival for patients with CF.


'/>"/>

Contact: Suzy Martin
smartin@thoracic.org
212-315-8631
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
2. Albemarle to Increase Price of Ibuprofen
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
5. Study, meta-analysis examine factors associated with death from heatstroke
6. Increased distance to physician associated with thicker skin cancer at diagnosis
7. Minorities more likely to have sleep durations associated with increased mortality
8. Income inequality associated with overnourishment and undernourishment in India
9. Maternal depression and controlling behavior associated with increased stress response in infants
10. Nurses describe dedication, frustration associated with their jobs
11. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology: